| Identification | Back Directory | [Name]
1,2-Benzenediol, 3,4-dibromo-5-[5-[4-(4-ethoxyphenoxy)phenyl]-2-oxazolyl]- | [CAS]
2097148-94-0 | [Synonyms]
1,2-Benzenediol, 3,4-dibromo-5-[5-[4-(4-ethoxyphenoxy)phenyl]-2-oxazolyl]- | [Molecular Formula]
C23H17Br2NO5 | [MOL File]
2097148-94-0.mol | [Molecular Weight]
547.19 |
| Chemical Properties | Back Directory | [Boiling point ]
645.6±65.0 °C(predicted) | [density ]
1.626±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
6.30±0.45(predicted) |
| Hazard Information | Back Directory | [Uses]
LXQ46 is an orally active inhibitor for protein tyrosine phosphatase 1B (PTP1B), with an IC50 of 0.190 μM. LXQ46 enhances insulin and leptin signaling pathways in insulin-resistant C2C12. LXQ46 ameliorates type 2 diabetes and increases insulin tolerance in mouse models[1]. | [References]
[1] Li X, et al., Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors. Eur J Med Chem. 2019 Mar 15;166:178-185. DOI:10.1016/j.ejmech.2019.01.057 |
|
|